{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:37:08Z","timestamp":1786405028109,"version":"build-2736575974"},"reference-count":42,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,5,19]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to provide insight into differences in drug review decisions made by the US Food and Drug Administration\u2019s (FDA) accelerated approval (AA) pathway and the European Medicines Agency\u2019s (EMA) conditional marketing authorisation (CMA) pathway, and to add to the current knowledge base of drug approval processes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design, setting, participants<\/jats:title>\n                  <jats:p>This cross-sectional study thoroughly examines novel oncology drugs with dual approval through FDA AA and EMA CMA between 2006 and 2021. Statistical analysis was performed from June to July 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary and secondary outcome measures<\/jats:title>\n                  <jats:p>The study examined the regulatory differences between regions for dually approved novel oncology drugs, including approval decisions, pivotal efficacy clinical trials, speed of review and postmarketing obligations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During this time period, there was a difference in the use of the FDA AA and the EMA CMA (FDA: EMA: 41.2%: 70.0%, p&lt;0.05). Of the 25 drugs approved by both the FDA AA and the EMA CMA, 22 (88.0%) of the regulatory decisions were based on the same pivotal clinical trials. But there were more differences in the requirements for postmarketing obligations, with the EMA\u2019s postmarketing obligations focusing on the efficacy and safety of the drug (EMA: FDA: 63.0%: 27.0%, p\uff1c0.05) and the FDA\u2019s postmarketing obligations focusing more on the efficacy (FDA: EMA: 73.0%: 23.9%, p\uff1c0.05). In addition, both the USA and EU had some postmarketing obligations completed beyond the schedule (30.4% and 19.2% in the USA and EU, respectively), with the longest delays lasting 3.7 years (0.2\u20133.7 years) and 3.3 years (0.04\u20133.3 years) in the USA and EU, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The FDA and EMA have different orientations and benefit\u2013risk balance considerations in the use of AA or CMA. It is also the case that the shortcomings in the design and implementation of postmarketing studies have made it a challenge to obtain the evidence needed to confirm a drug\u2019s benefits.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-069132","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T12:41:55Z","timestamp":1686141715000},"page":"e069132","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006\u20132021: a cross-sectional study"],"prefix":"10.1136","volume":"13","author":[{"given":"Jinping","family":"Xie","sequence":"first","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"},{"name":"NMPA Key Laboratory for Drug Regulatory Innovation and Evaluation, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-474X","authenticated-orcid":false,"given":"Jinlian","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"},{"name":"NMPA Key Laboratory for Drug Regulatory Innovation and Evaluation, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Shao","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Science for Medical Products, China Pharmaceutical University, Nanjing, Jiangsu, China"},{"name":"NMPA Key Laboratory for Drug Regulatory Innovation and Evaluation, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2025101814344076000_13.6.e069132.1","unstructured":"World Health Organization . World cancer report 2020: World Health Organization\/International agency for research on cancer (WHO\/IARC). 2020. Available: https:\/\/www.iarc.who.int\/faq\/latest-global-cancer-data-2020-qa\/ [Accessed 14 Jul 2022]."},{"key":"2025101814344076000_13.6.e069132.2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.drudis.2014.08.007","article-title":"An analysis of FDA-approved drugs for oncology","volume":"19","author":"Kinch","year":"2014","journal-title":"Drug Discov Today"},{"key":"2025101814344076000_13.6.e069132.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9415"},{"key":"2025101814344076000_13.6.e069132.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1248"},{"key":"2025101814344076000_13.6.e069132.5","unstructured":"Food and Drug Administration safety and innovation act. 2020. Available: https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-112publ144\/pdf\/PLAW-112publ144.pdf [Accessed 23 Jun 2022]."},{"key":"2025101814344076000_13.6.e069132.6","first-page":"1714","article-title":"Comparison and reference of foreign new drug special review models","volume":"51","author":"Xuefang","year":"2016","journal-title":"Chin J Pharm"},{"key":"2025101814344076000_13.6.e069132.7","first-page":"132","article-title":"A study on the new drug marketing approval process based on Surrogate endpoints in the US and EU and its implications","volume":"31","author":"Li","year":"2022","journal-title":"Chin New Drugs J"},{"key":"2025101814344076000_13.6.e069132.8","first-page":"289","article-title":"The connotation and risk prevention and control of conditional approval of drug listing","volume":"23","author":"Hui","year":"2021","journal-title":"Chin Pharm J"},{"key":"2025101814344076000_13.6.e069132.9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6854"},{"key":"2025101814344076000_13.6.e069132.10","first-page":"961","article-title":"A study on the policy of accelerated review and approval of new drug launches in China, the United States and Europe","volume":"29","author":"Xiaoxing","year":"2020","journal-title":"Chin J New Drugs"},{"key":"2025101814344076000_13.6.e069132.11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12940"},{"key":"2025101814344076000_13.6.e069132.12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33601","article-title":"Comparison of duration of postapproval vs pivotal trials for therapeutic agents granted US food and Drug Administration accelerated approval, 2009-2018","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025101814344076000_13.6.e069132.13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11606-018-4779-x","article-title":"Timeliness of postmarket studies for new pharmaceuticals approved between 2009 and 2012: a cross-sectional analysis","volume":"34","author":"Wallach","year":"2019","journal-title":"J Gen Intern Med"},{"key":"2025101814344076000_13.6.e069132.14","unstructured":"US food and Drug Administration . Clinical trial endpoints for use in medical product development. 2018. Available: https:\/\/cersi.umd.edu\/sites\/cersi.umd.edu\/files\/S01%20-%2003%20Papadopoulos.pdf [Accessed 06 May 2023]."},{"key":"2025101814344076000_13.6.e069132.15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5403"},{"key":"2025101814344076000_13.6.e069132.16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.39336","article-title":"Use of US food and Drug Administration expedited drug development and review programs by orphan and Nonorphan novel drugs approved from 2008 to 2021","volume":"5","author":"Monge","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025101814344076000_13.6.e069132.17","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/ijc.34473","article-title":"The evidence base of US food and Drug Administration approvals of novel cancer therapies from 2000 to 2020","volume":"152","author":"Gloy","year":"2023","journal-title":"Int J Cancer"},{"key":"2025101814344076000_13.6.e069132.18","doi-asserted-by":"publisher","DOI":"10.2165\/11318980-000000000-00000"},{"key":"2025101814344076000_13.6.e069132.19","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1565"},{"key":"2025101814344076000_13.6.e069132.20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16183","article-title":"Cancer therapy approval Timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010-2019","volume":"5","author":"Lythgoe","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025101814344076000_13.6.e069132.21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/bmj.o693","article-title":"High US drug prices have global implications","volume":"376","author":"Jenei","year":"2022","journal-title":"BMJ"},{"key":"2025101814344076000_13.6.e069132.22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt512"},{"key":"2025101814344076000_13.6.e069132.23","unstructured":"European Medicines Agency . Conditional marketing authorization: report on ten years of experience at the European medicines agency. 2017. Available: https:\/\/www.ema.europa.eu\/en\/documents\/report\/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf [Accessed 23 Jun 2022]."},{"key":"2025101814344076000_13.6.e069132.24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpt.174","article-title":"Use of the conditional marketing authorization pathway for oncology medicines in Europe","volume":"98","author":"Hoekman","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2025101814344076000_13.6.e069132.25","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.14"},{"key":"2025101814344076000_13.6.e069132.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j1680","article-title":"Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review","volume":"357","author":"Pease","year":"2017","journal-title":"BMJ"},{"key":"2025101814344076000_13.6.e069132.27","unstructured":"US Food and Drug Administration . Postmarket drug and biologic safety evaluations. 2019. Available: https:\/\/www.fda.gov\/drugs\/surveillance\/postmarket-drug-and-biologic-safety-evaluations [Accessed 21 Jun 2022]."},{"key":"2025101814344076000_13.6.e069132.28","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/jamainternmed.2021.4604","article-title":"Fulfilling the mandate of the US Food and Drug Administration\u2019s accelerated approval pathway: the need for reforms","volume":"181","author":"Gyawali","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025101814344076000_13.6.e069132.29","first-page":"2294","article-title":"Implications of the accelerated drug approval process in the United States for drug regulation in China","volume":"29","author":"Chenyang","year":"2020","journal-title":"Chin New Drugs J"},{"key":"2025101814344076000_13.6.e069132.30","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The on-and off-ramps of oncology accelerated approval","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101814344076000_13.6.e069132.31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1470-2045(23)00020-7","article-title":"Modernising the US FDA\u2019s accelerated approval pathway","volume":"24","author":"Benjamin","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025101814344076000_13.6.e069132.32","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12476"},{"key":"2025101814344076000_13.6.e069132.33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2010-S1-13","article-title":"The role of the US Food and Drug Administration review process: clinical trial endpoints in oncology","volume":"15 Suppl 1","author":"McKee","year":"2010","journal-title":"Oncologist"},{"key":"2025101814344076000_13.6.e069132.34","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025101814344076000_13.6.e069132.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.012"},{"key":"2025101814344076000_13.6.e069132.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative Confirmatory trials of accelerated approval cancer drugs: retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"2025101814344076000_13.6.e069132.37","unstructured":"US Food and Drug Administration . November 6, 2020 BLA 761178: peripheral and central nervous system drugs advisory committee meeting. 2012. Available: https:\/\/www.fda.gov\/media\/143505\/download [Accessed 23 Jun 2022]."},{"key":"2025101814344076000_13.6.e069132.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.012"},{"key":"2025101814344076000_13.6.e069132.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002873","article-title":"The use of validated and nonvalidated surrogate endpoints in two European medicines agency expedited approval pathways: a cross-sectional study of products authorised 2011\u20132018","volume":"16","author":"Schuster Bruce","year":"2019","journal-title":"PLoS Med"},{"key":"2025101814344076000_13.6.e069132.40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/bmj.n156","article-title":"Effect of reductions in Amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis","volume":"372","author":"Ackley","year":"2021","journal-title":"BMJ"},{"key":"2025101814344076000_13.6.e069132.41","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and Biologics: a review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025101814344076000_13.6.e069132.42","unstructured":"Friends of Cancer Research . Optimizing the use of accelerated approval. 2020. Available: https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Optimizing_the_Use_of_Accelerated_Approval-2020.pdf [Accessed 23 Jun 2022]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-069132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:34:50Z","timestamp":1760823290000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-069132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjopen-2022-069132"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-069132","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}